Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F21%3A10421147" target="_blank" >RIV/00669806:_____/21:10421147 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/21:10421147

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5-I6nQ4M6~" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5-I6nQ4M6~</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00066-020-01740-7" target="_blank" >10.1007/s00066-020-01740-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy

Popis výsledku v původním jazyce

PURPOSE: We aimed to find metabolic, functional or morphological characteristics of the tumor predicting failure to achieve complete metabolic remission (CMR) by the midtreatment PET/MRI (positron emission tomography/magnetic resonance imaging) in cervical cancer patients. METHODS: We evaluated 66 patients treated between August 2015 and November 2019 who underwent pretreatment staging, subsequent midtreatment evaluation, and definitive restaging 3 months after completing the whole treatment, all using PET/MRI. The pretreatment parameters (pre-SUVmax, pre-SUVmean, pre-MTV, pre-MTV-S, pre-TLG, pre-TLG-S [SUV: standard uptake value, MTV: metabolic tumor volume, TLG: total lesion glycolysis]), and the midtreatment parameters at week 5 during chemoradiotherapy (mid-SUVmax, mid-SUVmean, mid-MTV, mid-MTV-S, mid-TLG and mid-TLG-S) were recorded. The value of ADC (apparent diffusion coefficient) was also measured. Furthermore, we recorded absolute and relative changes in all parameters-INCREMENT and INCREMENT %. We divided the whole group of patients into &quot;responders&quot; (CMR) and &quot;non-responders&quot; (non-CMR), and compared them on the basis of the parameters from pre-PET/MRI and mid-PET/MRI. RESULTS: A statistically significant difference in the evaluated parameters between responders and non-responders was found for the following parameters: mid-MTV, mid-TLG, mid-TLG-S, mid-MTV-S, mid-tumor size, and INCREMENT %SUVmax. According to the ROC (receiver operating characteristic) analysis, mid-MTV-S showed the best albeit moderate discrimination ability for the prediction of non-CMR. Significant mutual correlations of all variables, in particular between mid-MTV-S and mid-TLG-S and between mid-MTV and mid-TLG, were found (all p &lt; 0.05). CONCLUSION: Our study confirmed that when using the midtreatment PET/MRI we are able to identify metabolic parameters having the discrimination ability for the prediction of non-CMR. In particular mid-MTV-S, mid-MTV, mid-tumor size, mid-TLG-S, mid-TLG and INCREMENT %SUVmax.

Název v anglickém jazyce

Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy

Popis výsledku anglicky

PURPOSE: We aimed to find metabolic, functional or morphological characteristics of the tumor predicting failure to achieve complete metabolic remission (CMR) by the midtreatment PET/MRI (positron emission tomography/magnetic resonance imaging) in cervical cancer patients. METHODS: We evaluated 66 patients treated between August 2015 and November 2019 who underwent pretreatment staging, subsequent midtreatment evaluation, and definitive restaging 3 months after completing the whole treatment, all using PET/MRI. The pretreatment parameters (pre-SUVmax, pre-SUVmean, pre-MTV, pre-MTV-S, pre-TLG, pre-TLG-S [SUV: standard uptake value, MTV: metabolic tumor volume, TLG: total lesion glycolysis]), and the midtreatment parameters at week 5 during chemoradiotherapy (mid-SUVmax, mid-SUVmean, mid-MTV, mid-MTV-S, mid-TLG and mid-TLG-S) were recorded. The value of ADC (apparent diffusion coefficient) was also measured. Furthermore, we recorded absolute and relative changes in all parameters-INCREMENT and INCREMENT %. We divided the whole group of patients into &quot;responders&quot; (CMR) and &quot;non-responders&quot; (non-CMR), and compared them on the basis of the parameters from pre-PET/MRI and mid-PET/MRI. RESULTS: A statistically significant difference in the evaluated parameters between responders and non-responders was found for the following parameters: mid-MTV, mid-TLG, mid-TLG-S, mid-MTV-S, mid-tumor size, and INCREMENT %SUVmax. According to the ROC (receiver operating characteristic) analysis, mid-MTV-S showed the best albeit moderate discrimination ability for the prediction of non-CMR. Significant mutual correlations of all variables, in particular between mid-MTV-S and mid-TLG-S and between mid-MTV and mid-TLG, were found (all p &lt; 0.05). CONCLUSION: Our study confirmed that when using the midtreatment PET/MRI we are able to identify metabolic parameters having the discrimination ability for the prediction of non-CMR. In particular mid-MTV-S, mid-MTV, mid-tumor size, mid-TLG-S, mid-TLG and INCREMENT %SUVmax.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/EF17_048%2F0007280" target="_blank" >EF17_048/0007280: Aplikace moderních technologií v medicíně a průmyslu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Strahlentherapie und Onkologie

ISSN

0179-7158

e-ISSN

—

Svazek periodika

197

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

11

Strana od-do

494-504

Kód UT WoS článku

000611412600001

EID výsledku v databázi Scopus

2-s2.0-85099744780